Squamous cell carcinoma

Advanced squamous cell carcinoma (aSCC)

Therapy: The investigational drug is an inhibitor of programmed cell death ligand 1 (PD-L1) that is administered orally in tablet form. The innovative therapy is an immunotherapy that works in conjunction with the body’s own defense system. Due to oral administration and lack of immunogenicity, it is expected to be better tolerated. The innovative therapy is intended for patients with advanced squamous cell carcinoma of the skin.

Why participate in the study:

  • The innovative therapy is an immunotherapy that works in conjunction with the body’s own defense system.
  • Better tolerability is expected for the innovative therapy due to the absence of immunogenicity.
  • The innovative therapy is free of charge and administered orally in tablet form, reducing the need for doctor visits for therapy administration (e.g., injection-based administration).

From what date can you participate? October 2023.

Newsletter

Receive regular notifications about our activities and news in treatments.

Free examinations